Amgen (AMGN) Long-Term Investments (2013 - 2014)

Amgen (AMGN) posted quarterly Long-Term Investments of $3.4 billion for Q1 2014, little changed on a QoQ basis from $3.4 billion in Q4 2013.

Amgen (AMGN) Long-Term Investments (2013 - 2014) Analysis & Trends

Amgen (AMGN) has reported Long-Term Investments for 2 consecutive years, with $3.4 billion the latest figure, recorded in Q1 2014.

In Q1 2014, Long-Term Investments changed N/A year-over-year to $3.4 billion; the TTM figure through Mar 2014 stood at $3.4 billion (changed N/A YoY), while the FY2013 annual figure was $3.4 billion, changed N/A from the prior year.
Long-Term Investments came in at $3.4 billion for Q1 2014 at Amgen, roughly flat from $3.4 billion in the prior quarter.
The five-year high for Long-Term Investments was $3.4 billion in Q1 2014, with the low at $3.4 billion in Q3 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	3.12 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	-
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	268.00 Mn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	-12.00 Mn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	1.11 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	-
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	983.00 Mn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	1.63 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-24.00 Mn
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn	465.60 Mn

Download Data